IHS Chemical Week

Chemical Week Magazine :: Companies

FDA tightens control over India’s API manufacturers More warning letters issued

8:27 AM MDT | June 27, 2014 | —Deepti Ramesh

FDA has, since 2013, issued warning letters to several active pharmaceutical ingredient (API) manufacturing facilities in India. FDA issues such a letter when an agency inspection of a facility identifies significant deviations from cGMP and the company that owns the facility fails to take sufficiently correct the issues. Until all corrections are completed, FDA may withhold approving any new drugs that list that firm as an API manufacturer or refuse to admit APIs manufactured at that facility into the United States. These separate warning letters include those...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa